Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yiwen Luo
Observed names:
Luo, Yiwen,
Y. Luo,
Yi-Wen Luo
Institution:
Merck & Co., Inc., Rahway, NJ, USA (United States)
Observed institutions:
Merck & Co., Inc., Rahway, NJ, USA (United States),
North Carolina State University,
Meso Scale Discovery (United States)
ORCID:
0000-0002-5187-6841
Observed ORCID:
0000-0002-5187-6841
OpenAlex ID:
A5102397464
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
2020
·
Charles M. Rudin
, Mark M. Awad
, et al.
·
Journal of Clinical Oncology
·
829
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
2024
·
James Chih-Hsin Yang
, Dae Ho Lee
, et al.
·
Journal of Clinical Oncology
·
243
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
2023
·
Quincy Chu
, Francesco Perrone
, et al.
·
The Lancet
·
139
Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
2023
·
James Chih-Hsin Yang
, Dae Ho Lee
, et al.
·
Journal of Clinical Oncology
·
104
Maternal blood cadmium, lead and arsenic levels, nutrient combinations, and offspring birthweight
2017
·
Yiwen Luo
, Lauren E. McCullough
, et al.
·
BMC Public Health
·
98
PDF
Cadmium exposure increases the risk of juvenile obesity: a human and zebrafish comparative study
2018
·
Adrian J. Green
, Cathrine Hoyo
, et al.
·
International Journal of Obesity
·
89
PDF
KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).
2020
·
Charles M. Rudin
, Mark M. Awad
, et al.
·
Journal of Clinical Oncology
·
28
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study
2025
·
Roy S. Herbst
, Byoung Chul Cho
, et al.
·
Journal of Thoracic Oncology
·
22
PDF
120MO Adjuvant pembrolizumab versus placebo for early-stage NSCLC after resection and optional chemotherapy: Updated results from PEARLS/KEYNOTE-091
2023
·
B. Besse
, L. Havel
, et al.
·
Immuno-Oncology Technology
·
19
PDF
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study
2024
·
Michael Boyer
, Rina Hui
, et al.
·
BMC Cancer
·
17
PDF
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC
2023
·
Hye Ryun Kim
, Mark M. Awad
, et al.
·
JTO Clinical and Research Reports
·
11
PDF
Complete Effect‐Profile Assessment in Association Studies With Multiple Genetic and Multiple Environmental Factors
2014
·
Zhi Wang
, Arnab Maity
, et al.
·
Genetic Epidemiology
·
10
ECHO-306/KEYNOTE-715: A phase 3 study of first-line epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus platinum-based chemotherapy plus placebo for metastatic non–small cell lung cancer (mNSCLC).
2018
·
Rina Hui
, Mihaela Munteanu
, et al.
·
Journal of Clinical Oncology
·
7
On the substructure controls in rare variant analysis: Principal components or variance components?
2017
·
Yiwen Luo
, Arnab Maity
, et al.
·
Genetic Epidemiology
·
7
64O Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy for metastatic non squamous non-small cell lung cancer (NSCLC): Phase III LEAP-006 study
2023
·
R.S. Herbst
, B.C. Cho
, et al.
·
Immuno-Oncology Technology
·
6
PDF
Advancements in hyaluronic acid cross-linking modalities and implant strategies for mitigating skin aging
2024
·
Zi-Bo Chen
, Yi-Wen Luo
, et al.
·
Biomedical Engineering Communications
·
5
Number of Repetitions in Re‐Randomization Tests
2024
·
Yilong Zhang
, Yujie Zhao
, et al.
·
Pharmaceutical Statistics
·
5
PDF
1782MO Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC
2020
·
H.R. Kim
, M.M. Awad
, et al.
·
Annals of Oncology
·
4
OA12.02 CCTG IND227, a Randomized Trial of Chemotherapy + Pembrolizumab in Advanced Pleural Mesothelioma: Updated Analyses
2025
·
S. Laurie
, Q. Chu
, et al.
·
Journal of Thoracic Oncology
193TiP Phase 3 study of epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus chemotherapy for first-line metastatic non-small cell lung cancer (mNSCLC): ECHO-306/KEYNOTE-715
2018
·
M. Garassino
, S. Rubin
, et al.
·
Journal of Thoracic Oncology
Statistical Methods to Study Association between Environmental, Epigenetic and Genetic Risk Factors and Child Health.
2017
·
Yiwen Luo
·
NCSU Libraries Repository (North Carolina State University Libraries)
母体血中カドミウム,鉛及びヒ素レベル,栄養素組合せ及び子孫出生体重【jst・京大機械翻訳】
2017
·
Yiwen Luo
, E McCullough Lauren
, et al.
·
BMC Public Health
Additional file 2: Table S1. of Maternal blood cadmium, lead and arsenic levels, nutrient combinations, and offspring birthweight
2017
·
Luo, Yiwen
, McCullough, Lauren
, et al.
·
Figshare
Show more works
View as search
Works count:
31
Citation count:
1,643
H-index:
11
I10-index:
12
Year
Topic
Type